awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38827600-0CE340EF-EAE6-4361-B794-8FA77C13885C
Q38827600-0CE340EF-EAE6-4361-B794-8FA77C13885C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38827600-0CE340EF-EAE6-4361-B794-8FA77C13885C
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l
P2860
Q38827600-0CE340EF-EAE6-4361-B794-8FA77C13885C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38827600-0CE340EF-EAE6-4361-B794-8FA77C13885C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
215b92af71e930284b307511b90d741e00811b48
P2860
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity